Not logged in, please login to view portfolio!

Sarmaaya Trainings


GSKCH Share Price | GlaxoSmithKline Consumer Healthcare

GSKCH Share Price History

GSKCH (GlaxoSmithKline Consumer Healthcare) listed in PSX,KSE100,ALLSHR,KMIALLSHR. GSKCH share price / stock price today is 205.08 PKR. Today volume traded in GSKCH is 5.1 K, price change is -1.76%, high price is 207.00 PKR, and low price is 205.00 PKR.

Company Snapshot

loading
GSKCH
2022-11-28 15:33:07
Current
205.08
Change
-3.67
Change %
-1.76%
Volume
5100
Price to Earnings Ratio
56.65
Earning per Share
3.62
Book Value
56.78
Price to Book
3.84
Market Cap
24.01 B
Dividend
0.00
Dividend Yield (%)
0.00 %
Debt to Equity
0.00
Net Profit Margin
1.57 %
Gross Profit Margin
19.17 %
Current Ratio
1.37
Face Value
10.00
Shares
117.05 M
FreeFloat
15.61 M
Free Float %
13.34
Equity to Asset(%)
43.85
Interest
4.37
Beta
0.85
Upper/Lower Cap
224.41 / 193.09
Times-Revenue Method New
52 Week High
274.99
52 Week Low
205.00
High
207.00
Low
205.00
Previous
208.75
loading

Company Brands

image
image
image
image
image
image
GSKCH Performance
Return (%) Absolute Return
1 Week 1 Month 3 Month 6 Month 1 Year
Return -3.519% 2.494% -3.601% -11.642% -14.027%

Company Financials
Company Announcements
Date Announce Title Attachments
2022-11-25 Notice of Board Meeting Other Than Financial Results View PDF
2022-11-14 Notice of Extraordinary General Meeting - 2022 View PDF
2022-11-11 Prior Publication of Extraordinary General Meeting Notice - 2022 View PDF
2022-11-10 Material Information - Appointment of Non-Executive Director View PDF
2022-11-04 Lifting of Force Majeure - Panadol Tablets, Panadol Extra Tablets and Children s Panadol Liquid Range View PDF
2022-11-02 Notice of Corporate Briefing Session 2022 - Revised Date View PDF
2022-10-27 Notice of Corporate Briefing Session - 2022 View PDF
2022-10-27 Transmission of Quarterly Report for the Period Ended 30 September 2022 View PDF
2022-10-21 Force Majeure - Panadol Tablets, Panadol Extra Tablets and Children s Panadol Liquid Range View PDF
2022-10-21 Financial Results for the Quarter Ended 30 September 2022 View PDF
2022-10-13 Notice of Board of Directors Meeting - (Q3-2022) View PDF
2022-09-16 Panadol - Material Information View PDF
2022-08-29 Transmission of Half Yearly Report for the Period Ended 30 June 2022 View PDF
2022-08-24 Notice of Update in Email Address for Shareholders View PDF
2022-08-23 BoD Approval of Change of Company Name View PDF
2022-08-23 Financial Results for the Quarter Ended 30 June 2022 View PDF
2022-08-15 Notice of Board of Directors Meeting - (Q2-2022) View PDF
2022-07-29 Demerger of Haleon plc and Change in Ultimate Parent of the Company View PDF
2022-06-22 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2022-06-16 Notice of Change in Email Address for Shareholders View PDF
2022-06-15 Reminder for Mandatory Conversion of Physical Shares to Book-Entry Form View PDF
2022-06-14 Change in Registered Office Address View PDF
2022-06-14 Prior Publication of Conversion of Physical Shares to Book Entry Form View PDF
2022-05-20 Material Information View PDF
2022-04-27 Transmission of Quarterly Report for the Period Ended 31 March 2022 View PDF
2022-04-25 Financial Results for the Quarter Ended 31 March 2022 View PDF
2022-04-22 Board Meeting in Progress View PDF
2022-03-31 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2022-03-14 Notice of Election of Directors View PDF
2022-03-11 Prior Publication of Notice of Election of Directors View PDF
2022-02-28 Notice of Annual General Meeting - 2021 View PDF
2022-02-28 Transmission of the Annual Report for the Year Ended 2021 View PDF
2022-02-25 Prior Publication of AGM Notice for the year 2021 View PDF
2022-02-09 Financial Results for the Year Ended 31 December 2021 View PDF
2022-02-03 Board of Directors Meeting - (Q4-2021) View PDF
2022-02-02 23rd Board of Directors Meeting REVOKED View PDF
2022-02-02 23rd Board of Directors Meeting View PDF
2021-12-24 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2021-11-11 Notice of Corporate Briefing Session 2021 View PDF
2021-10-29 Transmission of Quarterly Report for the Period Ended 30 September 2021 View PDF
2021-10-26 Financial Results for the Quarter Ended 30 September 2021 View PDF
2021-10-15 Notice of Board Meeting (Q3-2021) View PDF
2021-09-15 Mandatory Conversion of Physical Shares to Book-Entry Form View PDF
2021-09-08 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2021-09-08 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations REVOKED View PDF
2021-09-08 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2021-08-27 Transmission of Half-Yearly Report for the Period Ended 30 June 2021 View PDF
2021-08-24 Financial Result for the Quarter Ended 2021-06-30 View PDF
2021-08-13 Notice of Board Meeting (Q2-2021) View PDF
2021-05-05 Credit of Final Cash Dividend - YE 31 Dec 2020 View PDF
2021-05-04 Prior Publication of Dividend Notice View PDF
2021-04-30 GSKCH | GlaxoSmithKline Consumer Healthcare Pakistan Limited PDF
2021-04-29 Transmission of Quarterly Report for the Period Ended 31 March 2021 View PDF
2021-04-23 Financial Results for the Quarter Ended 2021-03-31 View PDF
2021-04-22 Resolution passed by the Shareholders in the Annual General Meeting. View PDF
2021-04-16 Notice of Board Meeting (Q1-2021) View PDF
2021-04-01 Change of Chief Executive Officer View PDF
2021-03-31 Transmission of Annual Report for the Year Ended 2020 View PDF
2021-03-31 Notice of Annual General Meeting View PDF
2021-03-30 Prior Publication of AGM Notice REVOKED View PDF
2021-03-30 Prior Publication of AGM Notice View PDF
2021-03-30 Prior Publication of AGM Notice View PDF
2021-03-25 Revised Book Closure View PDF
2021-03-05 Financial Results for the Year Ended December 31, 2020 View PDF
2021-03-04 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View PDF
2021-03-03 Appointment of Non-Executive Independent Director View PDF
2021-03-01 Board Meeting - Q4-2020 View PDF
2021-02-08 Material Information PDF
2021-02-04 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations PDF
2021-02-01 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations PDF
2021-02-01 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations REVOKED PDF
2021-02-01 Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations PDF

About Company

GlaxoSmithKline Consumer Healthcare Pakistan Limited was incorporated in Pakistan as a public unlisted company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017). The Company is a subsidiary of GlaxoSmithKline Consumer Healthcare B.V. The ultimate parent of the Company is GlaxoSmithKline plc, UK. The Company is engaged in manufacturing, marketing and sale of consumer healthcare products.

Address
35 – Dockyard Road, West Wharf,
Website
www.pk-consumerhealthcare.gsk.co
Key People
Mr. M.Z. Moin Mohajir Chairperson
Mr. Sohail Matin CEO
Ms. Mashal Mohammad Company Secretary

Page description

GSKCH (GlaxoSmithKline Consumer Healthcare) listed in PSX,KSE100,ALLSHR,KMIALLSHR. GSKCH Share Price / Stock Price is 205.08 PKR. You can also check; Share Price History, GSKCHPayouts, Annoucements, Snapshot, Company details, Fundamentals, Technicals and much more.

GSKCH Share Price GSKCH Stock Price GlaxoSmithKline Consumer Healthcare psx stock kse100 stock GSKCH Stock Price KSE100 ALLSHR KMIALLSHR Share price History GSKCH Payouts Annoucements Snapshot GSKCH Address GSKCH CEO Book Value Price/Book Ratio Dividend Yield Earning Per Share Net Profit Margin Gross Profit Margin Price to Sales Ratio Long Term Debt to Equity Interest Cover (Times) Equity to Assets (%) Current Ratio (Times) Cash Payout Ratio Technical Indicators Moving Averages GSKCH Chairperson GSKCH Secretary GSKCH Website About GSKCH

My Watchlist

Not logged in, please login to view watchlist!

Today's Market Performers KSE100

Change
loading

If you are someone who is keen on investments but does not have the time to research, identify stock market patterns, and keep track of stocks, forex, mutual funds, cryptocurrencies and other commodities like Gold and silver, then Sarmaaya is your meeting place, the crossroads where you can find everything you need to make the best decisions in the trading market. Based on unbiased, accurate and free information.

© 2022 SARMAAYA.PK

Sarmaaya Financials Private Limited is a Pakistan Stock Exchange (PSX) authorized data redistributor. Sarmaaya & CS Solutions (Pvt.) Limited (CS) do not guarantee the timeliness, accurateness, or completeness of any data or information on the website. Sarmaaya & CS makes no warranties, express or implied, as to Sarmaaya & CS or any data or values relating thereto or results to be obtained therefrom, and expressly disclaims all warranties of merchantability and fitness for a particular purpose with respect thereto. To the maximum extent allowed by law, Sarmaaya & CS, its licensors, and their respective employees, contractors, agents, suppliers and vendors shall have no liability or responsibility whatsoever for any injury or damages – whether direct, indirect, consequential, incidental, punitive or otherwise – arising in connection with Sarmaaya & CS or any data or values relating thereto – whether arising from their negligence or otherwise. Nothing in the website shall constitute or be construed as an offering of financial instruments or as investment advice or investment recommendations (i.e., recommendations as to whether or not to “buy”, “sell”, “hold”, or to enter or not to enter into any other transaction involving any specific interest or interests) by Sarmaaya & CS or a recommendation as to an investment or other strategy by Sarmaaya & CS. Data and other information available via the website should not be considered as information sufficient upon which to base an investment decision.